Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Critical Outcome Technologies has received confirmatory experimental results that have identified a novel and potentially first in class mechanism of action for its lead cancer drug candidate, COTI-2.
Subscribe to our email newsletter
Experiments conducted in triplicate have confirmed that COTI-2 has a profound effect on caspase-9 activation through inhibition of Akt/PKB. According to the company, the resulting activation of caspase-9 leads to a vigorous apoptosis or programmed cell death in cancer cells.
Wayne Danter, president and CSO of Critical Outcome Technologies, said: “The confirmation of a novel mechanism of action for COTI-2 represents a significant advancement for Critical Outcome Technologies (COTI) and our anti-cancer drug development program.”